1-6 of 6
Ding Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1/IL6/STAT3 Signaling Axis

Qian Wang, Shengnan Jia, Ding Wang, Xuyang Chen, Dhan V. Kalvakolanu, Hongwu Zheng, Xiaodong Wei, Naiyan Wen, Hang Liang, Baofeng Guo, Ling Zhang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (12): 2542–2553.
https://doi.org/10.1158/1535-7163.MCT-20-0037
Published: 02 December 2020
View article titled, A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1/IL6/STAT3 Signaling Axis
Open the PDF for A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1/IL6/STAT3 Signaling Axis in another window
Includes: Supplementary data
Journal Articles

Abstract A095: Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer

Raffit Hassan, Ding Wang, John Wrangle, Anish Thomas, Angus Byars, Lianne Asschert, Rolando Atienza, Prabhu Rajagopalan, Annette Walter, Jun Zhang, Nenad Sarapa, Hedy Kindler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A095.
https://doi.org/10.1158/1535-7163.TARG-17-A095
Published: 01 January 2018
View article titled, Abstract A095: Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer
Journal Articles

Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers

Ding Wang, Manish Patel, Marwan Fakih, A. Craig Lockhart, Anthony J. Olszanski, Rupal Patel, Peter D. Brown, Jennifer W. Oliver, Pratik S. Multani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C188.
https://doi.org/10.1158/1535-7163.TARG-15-C188
Published: 01 December 2015
View article titled, Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers
Journal Articles

Abstract C46: NSABP FC-7: A phase Ib study evaluating neratinib (N) and cetuximab (Cmab) in patients (pts) with quadruple wild-type (quad wt) (KRAS/NRAS/BRAF/PI3KCA wt) metastatic colorectal cancer (mCRC) resistant to Cmab

Samuel A. Jacobs, James J. Lee, Thomas J. George, Jr., James L. Wade, III, Philip J. Stella, Ding Wang, Ashwin R. Sama, Marc E. Buyse, Jodi A. Kanyuch, Ashok Srinivasan, Kay L. Pogue-Geile, S. Rim Kim, Norman Wolmark, Carmen J. Allegra
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C46.
https://doi.org/10.1158/1535-7163.TARG-15-C46
Published: 01 December 2015
View article titled, Abstract C46: NSABP FC-7: A phase Ib study evaluating neratinib (N) and cetuximab (Cmab) in patients (pts) with quadruple wild-type (quad wt) (KRAS/NRAS/BRAF/PI3KCA wt) metastatic colorectal cancer (mCRC) resistant to Cmab
Journal Articles

Abstract A91: A phase I dose-escalation study of bosutinib plus capecitabine in selected advanced solid tumors.

Steven Isakoff, Ding Wang, Mario Campone, Antonio Calles, Nathalie Bardy-Bouxin, Ladan Duvillie, Emiliano Calvo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A91.
https://doi.org/10.1158/1535-7163.TARG-11-A91
Published: 12 November 2011
View article titled, Abstract A91: A phase I dose-escalation study of bosutinib plus capecitabine in selected advanced solid tumors.
Journal Articles

Antitumor Activity of a Recombinant Soluble Ectodomain of Mutant Human Fibroblast Growth Factor Receptor-2 IIIc

Ju Wang, Xue-ting Liu, Hui Huang, Gang Xiao, Zhi-you Zhou, Yang Chen, Zhi-hong Yu, Shui-lian He, An-an Chen, Ding-ding Wang, Ying He, Zhi-cheng Zhang, An Hong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (9): 1656–1666.
https://doi.org/10.1158/1535-7163.MCT-11-0163
Published: 07 September 2011
View article titled, Antitumor Activity of a Recombinant Soluble Ectodomain of Mutant Human Fibroblast Growth Factor Receptor-2 IIIc
Open the PDF for Antitumor Activity of a Recombinant Soluble Ectodomain of Mutant Human Fibroblast Growth Factor Receptor-2 IIIc in another window